Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

IKT | Inhibikase Therapeutics Inc

Index- P/E- EPS (ttm)-4.17 Insider Own22.48% Shs Outstand4.20M Perf Week11.20%
Market Cap7.44M Forward P/E- EPS next Y-3.43 Insider Trans0.00% Shs Float4.15M Perf Month-33.01%
Income-19.03M PEG- EPS next Q-1.20 Inst Own18.52% Short Float / Ratio0.55% / 0.45 Perf Quarter-61.50%
Sales0.25M P/S29.75 EPS this Y23.61% Inst Trans-23.72% Short Interest0.02M Perf Half Y-65.91%
Book/sh3.68 P/B0.38 EPS next Y-3.94% ROA-67.55% Target Price27.00 Perf Year-74.26%
Cash/sh3.91 P/C0.36 EPS next 5Y- ROE-77.72% 52W Range0.95 - 6.94 Perf YTD-53.67%
Dividend- P/FCF- EPS past 5Y-76.13% ROI-97.02% 52W High-79.98% Beta0.89
Dividend %- Quick Ratio8.04 Sales past 5Y46.79% Gross Margin32.10% 52W Low46.24% ATR0.21
Employees6 Current Ratio8.04 Sales Q/Q1676.71% Oper. Margin-7850.03% RSI (14)37.60 Volatility9.62% 14.45%
OptionableNo Debt/Eq0.02 EPS Q/Q-0.18% Profit Margin-7557.69% Rel Volume0.68 Prev Close1.44
ShortableYes LT Debt/Eq0.01 EarningsAug 14 AMC Payout- Avg Volume50.78K Price1.39
Recom2.00 SMA20-17.11% SMA50-33.74% SMA200-58.62% Volume34,349 Change-3.47%
Sep-20-23 08:30AM
Aug-24-23 08:30AM
Aug-22-23 08:05AM
Aug-21-23 08:30AM
Aug-17-23 08:30AM
11:47PM Loading…
Aug-15-23 11:47PM
Aug-14-23 04:20PM
Aug-07-23 08:05AM
Jul-17-23 04:05PM
Jun-29-23 09:29AM
Jun-22-23 08:05AM
Jun-21-23 08:05AM
May-30-23 08:05AM
May-24-23 12:04PM
May-17-23 06:11AM
07:45AM Loading…
May-16-23 07:45AM
May-15-23 08:30AM
May-09-23 07:15AM
May-08-23 08:05AM
May-04-23 08:05AM
May-02-23 03:30PM
Apr-26-23 08:00AM
Apr-24-23 09:00AM
Apr-21-23 08:30AM
Apr-07-23 10:25PM
Mar-31-23 08:22AM
Mar-23-23 05:15PM
Mar-21-23 08:00AM
Mar-16-23 08:30AM
Mar-15-23 08:35AM
08:30AM Loading…
Mar-08-23 08:30AM
Feb-15-23 04:05PM
Feb-08-23 01:00PM
Jan-27-23 04:05PM
Jan-25-23 01:00PM
Dec-12-22 04:05PM
Dec-07-22 04:05PM
Nov-22-22 08:00AM
Nov-14-22 05:45PM
Nov-10-22 05:00AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Oct-12-22 08:00AM
Sep-21-22 04:05PM
Sep-15-22 08:00AM
Sep-13-22 12:15PM
Sep-08-22 08:30AM
Sep-01-22 04:05PM
Aug-26-22 08:00AM
Aug-23-22 08:00AM
Aug-12-22 04:55PM
Aug-08-22 08:30AM
Jun-13-22 08:00AM
May-16-22 05:00PM
May-10-22 08:05AM
May-09-22 04:05PM
Apr-21-22 04:05PM
Apr-13-22 11:45AM
Apr-06-22 11:37AM
Mar-31-22 05:00PM
Mar-28-22 08:00AM
Mar-25-22 08:00AM
Mar-23-22 08:00AM
Mar-08-22 08:00AM
Jan-05-22 08:30AM
Nov-29-21 08:05AM
Nov-15-21 05:30PM
Oct-27-21 08:05AM
Oct-19-21 08:05AM
Oct-04-21 09:57AM
Sep-23-21 08:05AM
Sep-07-21 08:00AM
Aug-16-21 04:45PM
Jul-26-21 10:09AM
Jun-18-21 06:45PM
Jun-16-21 08:00AM
Jun-15-21 07:40PM
May-25-21 08:00AM
May-17-21 04:05PM
Apr-21-21 08:00AM
Apr-01-21 08:00AM
Mar-02-21 08:05AM
Feb-22-21 08:05AM
Feb-17-21 12:48PM
Jan-04-21 08:01AM
Dec-28-20 10:33AM
Dec-23-20 05:12PM
Dec-22-20 06:25PM
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.